StockMarketWire.com - JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC [LON:HIK] and cut its price target to 1700p (from 1800p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk